At the very moment it looked like the market was down for the count, stocks bounced back. After being dealt hefty blows earlier in the week due to …
These 3 pharmas are rising on positive clinical results data
MLV’s healthcare analyst Vernon Bernardino today weighed in with his thoughts on BioCryst Pharmaceuticals (NASDAQ:BCRX), as the company announced positive results from evaluation of its broad spectrum …
In a research note issued today, analyst Vernon Bernardino of MLV reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a price target of $15, …
In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, …
In a research report issued Friday, Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price …
In a research report issued Friday, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (NASDAQ: BCRX) with a price target …
BioCryst Pharmaceuticals (BCRX) today announced the National Institute of Allergy and Infectious Diseases (NIAID) has exercised additional options to conduct Phase I clinical human safety …
In a research note issued August 6, Roth Capital analyst Ed Arce reiterated a Buy rating on BioCryst Pharmaceuticals (BCRX) with a $20 …
In a research report released yesterday, H.C.
